Radium-223 dichloride (Ra-223) is an alpha emitter with low toxicity for the treatment of patients with castrations-resistant prostate cancer (CRPC) and symptomatic bone metastases showing a 30% reduction in the risk of death, as compared to placebo.
Because of the favorable physical and chemical characteristics, Ra-223 can be handled easily in daily practice based on interdisciplinary co-operation between urology and nuclear medicine. Ra-223 has been approved under the product name Xofigo® by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).
Written by:
Heinzer H, König F, Klutmann S. Are you the author?
Prostatakrebszentrum, Martini-Klinik am Universitätsklinikum Hamburg-Eppendorf, Martinistraße 52, 20246, Hamburg, Deutschland.
Reference: Urologe A. 2014 Apr;53(4):519-23.
doi: 10.1007/s00120-014-3436-1
PubMed Abstract
PMID: PMID: 24604017
Article in German.
UroToday.com Bone Metastases Section
